Recent research has identified an antibody capable of blocking the growth of some tumors and preventing the spread of metastases. In particular, the data revealed that this antibody is able to block some specific tumors of the stomach, neck and esophagus.
Don't store avocado like this: it's dangerous
An international consortium of researchers discovered theMCLA-158 antibody, able to prevent the spread of cancer and metastases.
This antibody specifically blocks the spread of cancer to other organs, and slows the growth of cancer cells.
The research also lays the groundwork for incorporating the use of organoids in the drug discovery process. The latter are patient-derived samples that can be cultured, and that mimic the behavior of the tumor in the laboratory.
So far they have explored its usefulness in personalized cancer medicine, but to discover MCLA-158, researchers for the first time used an organoid biobank from cancer patients to discriminate, among hundreds of new antibodies, which was the most effective and suitable for most sufferers.
(Read also: Lung cancer: here are the microscopic worms that smell tumors before they show up)
A systematic review
The study investigated the safety, tolerability and anticancer activity of MCLA-158 monotherapy in head and neck squamous cell carcinomas (HNSCC).
In the study, three of the seven patients achieved partial remissions, with one achieving complete remission, while all seven still had a shrinkage of the tumor.
We started cancer stem cell research 15 years ago. The path to get here was exciting, but also very complex, and required a large investment of resources and the efforts of many researchers.
Antibodies are proteins that the body naturally produces to recognize infectious agents or altered cells, and which can be eliminated by lymphocytes the immune system (white blood cells).
The antibody described in this work, MCLA-158, is a bispecific substance that recognizes two different proteins in cancer stem cells, EGFR and LGR5.
EGFR activity promotes uncontrolled cell growth, while LGR5 marks the surface of cancer stem cells, responsible for disease expansion.
MCLA-158 degrades the EGFR protein in the cancer stem cells, which carry the LGR5 marker, and thus blocks the growth and survival pathways of the disease.
Furthermore, this antibody does not interfere with the functioning of healthy stem cells, which are essential for the proper functioning of tissues.
Preclinical data, therefore, indicate that MCLA-158 inhibits the growth of the organoids of colorectal cancer, and blocks the onset of metastasis and cancer growth in various cancer models, including the head and neck, esophagus and stomach.
Follow us on Telegram | Instagram | Facebook | TikTok | Youtube
Photos: Nature Cancer
Sul cancer could it be interesting for you:
- Uterine cancer: it would also be a question of being overweight! The risk doubles if you exceed this BMI
- Prostate Cancer: A bacterium in the urine may be the best signal for early diagnosis
- Pancreatic cancer: This signal in your stool could be a wake-up call not to be underestimated
- Colon cancer: The unusual symptom that occurs after eating could be a wake-up call
- Pancreatic cancer: This probiotic bacterium present in your gut causes it to unexpectedly grow
